NEW YORK, Sept. 15 (GenomeWeb News) - Dharmacon and Odyssey Thera have signed a collaboration to study gene silencing in cell signaling pathways, the companies said today.
Under the agreement, Dharmacon, of Lafayette, Colo., will synthesize its siRNA reagents for targets that Odyssey Thera, of San Ramon, Calif., provides. These targets are associated with angiogenesis, apoptosis, inflammation, and other disease-related events, the companies said.
Odyssey researchers will combine these siRNA reagents with the company's protein-fragment complementation assay, which is used to quantify and analyze signaling events in living human cells. Together, these technologies are expected to enable the researchers to analyze the way that gene silencing affects downstream events in cell signaling pathways, as well as measuring off-pathway effects.
Odyssey said it is planning to use the information gleaned through this collaboration in identification of novel targets, as well as potential nucleic acid and small molecule therapeutics, and high-throughput screening assays. Dharmacon said the collaboration will help it broaden its understanding of "the specificity and potency of siRNA's in the context of a cellular readout," according to a company statement.
The companies did not disclose the financial terms of the agreement.